One of the better-quality companies in the pharmaceutical sector, AbbVie ( ABBV 2.35%) had a phenomenal year in 2025.

AbbVie extended the patent life on Humira for years, enough time to more than replace the sales. Now Merck and Bristol Myers ...

ABBV has rebounded after Humira patent cliff, with Skyrizi and Rinvoq driving growth. Rising estimates and a pipeline set to ...

AbbVie’s lost exclusivity for Humira is offset by immunology and neurology sales, diversified by its emerging oncology pipeline.

The global pharmaceutical industry will generate more than $1.2 trillion in sales in 2026, according to Statista. The oncology segment alone is expected to generate $232 billion in sales this year.

The retailer increased its guidance for the year, anticipating more price-conscious shoppers would flock to its stores. By Jordyn Holman Good news for Walmart might be bad news for the U.S. economy.

AbbVie’s ABBV reported third-quarter 2025 results on Oct. 31, before market open. The company beat estimates for both earnings and sales. While sales rose 9.1% year over year, earnings declined 38% ...

Comments: Global sales from the immunology portfolio were $7.9 billion, up 12%. Skyrizi sales were $4.7 billion, up 47%. Rinvoq sales were $2.2 billion, up 35%. Humira sales were $993 million, down 55 ...

I’ve built a dividend-focused portfolio over 11 years for consistent quarterly income amid market ups and downs. The three stocks below offer reliable payouts with yields from 2.4% to 2.8% and ...